Collaborative Agreement Contract Value

No definition available.

Name:	bcrx_CollaborativeAgreementContractValue
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contract Term

+ References

No definition available.

+ Details

Name:	bcrx_ContractTerm
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement, Annual Global Net Sales

+ References

No definition available.

+ Details

Name:	bcrx_LicenseAgreementAnnualGlobalNetSales
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement, Number of Milestone Payments

+ References

No definition available.

+ Details

Name:	bcrx_LicenseAgreementNumberOfMilestonePayments
Namespace Prefix:	bcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement, Royalty Payment, Number of Tiers

+ References

No definition available.

+ Details

Name:	bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers
Namespace Prefix:	bcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement, Upfront Payment

+ References

No definition available.

+ Details

Name:	bcrx_LicenseAgreementUpfrontPayment
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The maximum percentage of customary reductions allowed on royalty rate.

+ References

No definition available.

+ Details

Name:	bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix:	bcrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Maximum Number Of Products Permitted To Be Obtained, Doses

+ References

No definition available.

+ Details

Name:	bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses
Namespace Prefix:	bcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Optional Ordering Periods

+ References

No definition available.

+ Details

Name:	bcrx_NumberOfOptionalOrderingPeriods
Namespace Prefix:	bcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Product Delivered, Doses

+ References

No definition available.

+ Details

Name:	bcrx_NumberOfProductDeliveredDoses
Namespace Prefix:	bcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential Milestone Payments Payable

+ References

No definition available.

+ Details

Name:	bcrx_PotentialMilestonePaymentsPayable
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Milestone Payments Payable If Regulatory Approval Before Milestone

+ References

No definition available.

+ Details

Name:	bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of potential milestone payments receivable if regulatory approval is granted.

+ References

No definition available.

+ Details

Name:	bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royalty Rate

+ References

No definition available.

+ Details

Name:	bcrx_RoyaltyRate
Namespace Prefix:	bcrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.

+ References

No definition available.

+ Details

Name:	bcrx_RoyaltyRateIfMaintainsSakigakeDesignation
Namespace Prefix:	bcrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOf2MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesGreaterThan15MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=bcrx_RAPIVABMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Relationships (Details) $ in Thousands			1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 03, 2023 USD ($) payment	Nov. 05, 2019 USD ($)	Sep. 30, 2024 USD ($) dose period	Jun. 30, 2025 USD ($) dose	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) dose	Jun. 30, 2024 USD ($)	Nov. 30, 2023
Collaborative and Other Relationships [Line Items]
Revenues				$ 163,353	$ 109,332	$ 308,887	$ 202,093
Torii Pharmaceutical Co.
Collaborative and Other Relationships [Line Items]
Revenues		$ 22,000
Potential milestone payments receivable if regulatory approval before specified date		$ 15,000
Maximum customary reduction on royalty rate		50.00%
Torii Pharmaceutical Co. \| Minimum
Collaborative and Other Relationships [Line Items]
Royalty rate if maintains sakigake designation		20.00%
Royalty rate								20.00%
Torii Pharmaceutical Co. \| Maximum
Collaborative and Other Relationships [Line Items]
Royalty rate if maintains sakigake designation		40.00%
Royalty rate								80.00%
Clearside Biomedical, Inc.
Collaborative and Other Relationships [Line Items]
Upfront payment	$ 5,000
Number of milestone payments \| payment	3
Number of royalties tiers \| payment	3
Clearside Biomedical, Inc. \| Annual Net Sales Of $2 Million
Collaborative and Other Relationships [Line Items]
Annual global net sales	$ 2,000,000
Clearside Biomedical, Inc. \| Annual Net Sales Greater Than $1.5 Million
Collaborative and Other Relationships [Line Items]
Annual global net sales	1,500,000
Clearside Biomedical, Inc. \| Maximum
Collaborative and Other Relationships [Line Items]
Potential milestone payment	30,000
Potential payment if milestone reached	$ 47,500
HHS Office of the Administration for Strategic Preparedness and Response
Collaborative and Other Relationships [Line Items]
Contract value			$ 69,388
Contract term			5 years
HHS Office of the Administration for Strategic Preparedness and Response \| RAPIVAB
Collaborative and Other Relationships [Line Items]
Revenues				$ 6,208		$ 12,206
Number of doses permitted to be procured \| dose			95,600
Contract term			12 months
Number of optional ordering periods \| period			4
Proceeds from collaborators			$ 13,878
Doses delivered \| dose				8,600		16,800